RVMD Revolution Medicines, Inc.
Price Chart
Executive Summary
Revolution Medicines announced that Phase 1/2 data for daraxonrasib in RAS-mutant pancreatic cancer were published in NEJM, complementing recently reported positive Phase 3 topline results showing an unprecedented overall survival benefit. The drug holds FDA Breakthrough Therapy and Orphan Drug Designations, reinforcing its potential as a new standard of care for a deadly cancer with limited treatment options.
Actionable Insight
Traders should expect upward price pressure as the market digests the positive clinical validation. Monitor for regulatory submission milestones and potential partnership or M&A interest given the high unmet need.
Key Facts
- NEJM published Phase 1/2 data for daraxonrasib in metastatic RAS-mutant PDAC.
- Company previously announced positive Phase 3 RASolute 302 topline results with unprecedented overall survival benefit vs. standard chemotherapy.
- Daraxonrasib has FDA Breakthrough Therapy and Orphan Drug Designations for PDAC with G12 mutations.
- Daraxonrasib is a RAS(ON) multi-selective inhibitor targeting diverse RAS mutations.
- Three additional global Phase 3 registrational trials are ongoing, including earlier-line PDAC and NSCLC.
Financial Impact
Positive clinical data significantly increases probability of regulatory approval and peak sales potential, estimated by analysts in the multi-billion dollar range for PDAC indication alone.
Risk Factors
- Regulatory approval not guaranteed; pivotal trial results may not replicate in larger populations.
- Competition from other RAS inhibitors (e.g., from Mirati, Amgen) could limit market share.
- Risk of toxicity or safety issues in ongoing broader clinical development.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3289496 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 11, 2026
3d ago
|
144
| $149.21 awaiting T+5 | awaiting T+5 | — | $153.87 (+3.12%) |
|
May 31, 2026
14d ago
|
Press Release
| $163.68 $149.23 | ▼ −8.83% | ▼ −6.08% | $153.87 (−5.99%) |
|
May 6, 2026
5w ago
|
Press Release
| $142.51 $149.94 | ▲ +5.21% | ▲ +3.71% | $153.87 (+7.97%) |
|
Apr 21, 2026
7w ago
|
Press Release
| $141.50 $140.80 | ▼ −0.49% | ▼ −0.55% | $153.87 (+8.74%) |
|
Apr 21, 2026
7w ago
|
Press Release
| $141.50 $140.80 | ▼ −0.49% | ▼ −0.55% | $153.87 (+8.74%) |
|
Apr 21, 2026
7w ago
|
Press Release
| $148.90 $144.83 | ▼ −2.73% | ▼ −3.82% | $153.87 (+3.34%) |
|
Apr 19, 2026
8w ago
|
Press Release
| $146.23 $131.67 | ▼ −9.96% | ▼ −10.87% | $153.87 (+5.22%) |
|
Apr 17, 2026
8w ago
|
Press Release
| $146.23 $131.67 | ▲ +9.96% | ▲ +10.87% | $153.87 (−5.22%) |
|
Apr 15, 2026
8w ago
|
Press Release
| $152.54 $141.50 | ▲ +7.24% | ▲ +8.88% | $153.87 (−0.87%) |
|
Apr 13, 2026
8w ago
|
Press Release
| $147.01 $148.90 | ▼ −1.29% | ▲ +0.11% | $153.87 (−4.67%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access